Uses of Olafast

Olanzapine is an antipsychotic active ingredient that has been used in the treatment of schizophrenia or to prevent relapse of bipolar disorder. This active ingredient is found in many different products, including Olafast. So what is Olafast and how is it used?

What is Olafast? Olafast is an antipsychotic product with the active ingredient Olanzapine. The dosage form of Olafast is film-coated tablets, content of 2.5, 5, 10 or 20mg with the packing specification of each box of 3 blisters x 10 tablets. Olafast is a product of Cure Medicines (I) Pvt Ltd (India), circulated in Vietnam with registration number VN-12784-11. The active ingredient Olanzapine in Olafast belongs to the antipsychotic group that acts on a number of receptor systems, including 5HT2A/2C, 5HT3, 5HT8 of Serotonin, D1, D2, D3, D4 and D5 of Dopamine, M1 to M5 of Muscarinic , α1-adrenergic and H1 of Histamine.

Olafast is indicated in the following cases:
Treatment of schizophrenia; Treatment of moderate and severe manic episodes; Prophylaxis of recurrence of bipolar disorder in patients with manic episodes who respond well to treatment with Olafast. Olafast is contraindicated in the following cases:
History of hypersensitivity to Olanzapine or any component of the preparation; Patients at high risk for angle-closure glaucoma.

Olafast is used orally and does not depend on meals.
The recommended dose of Olafast is as follows:
Adults: Schizophrenia: Initial dose is 10 mg/day; Manic phase: Initial dose is 15 mg/day as monotherapy or 10 mg/day in combination with other agents; Prevention of recurrence of bipolar disorder: The starting dose is 10 mg/day. If a patient has been taking Olafast for a manic episode, the same dose should be kept to prevent recurrence of bipolar disorder. In case of episodes of mania, depression or mixed disorder, continue treatment with Olafast (the dose can be adjusted) in combination with other supportive therapies to improve symptoms; In indications for the treatment of bipolar disorder, manic episodes or prevention of relapse of bipolar disorder, the dose of Olafast may vary from 5-20 mg/day, depending on the clinical condition. Dose adjustments above the starting dose should be made only after clinical evaluation and over a minimum period of 24 hours; When discontinuation is indicated, the dose of Olafast should be gradually reduced; Olafast dosage for patients with renal or hepatic impairment: The dose of Olafast should be reduced in these subjects. Patients with moderate hepatic impairment (eg, cirrhosis, Child-pugh grade A or B) should be initiated at 5 mg only and with caution when increasing the dose; When there is more than 1 factor that slows down the metabolism of Olanzapine (including gender, age, smoking habits, etc.), consideration should be given to initiating Olafast at a lower dose and cautiously increasing the dose. ; Pediatric dosage of Olafast: Not recommended for use in children under 18 years of age due to lack of data on safety and efficacy; Olafast Dosage in Elderly: No dose reduction is required, but a lower dose of Olafast (5 mg/day) should be considered in patients over 65 years of age or with concomitant clinical adverse events. Olafast overdose and management:
There is no specific antidote for Olanzapine, therefore treatment of Olafast overdose is mainly appropriate support; In cases of acute poisoning, the following considerations should be considered: keep airway open, ensure adequate oxygen supply, consider administration of activated charcoal (reduces oral bioavailability of Olanzapine) or possibly gastric lavage. thickening (after intubation in a comatose patient); Note that hemodialysis or hemodialysis does not remove much Olanzapine; Hypotension and cardiovascular collapse due to Olafast overdose should be treated with appropriate measures such as intravenous fluids or sympathomimetic agents such as norepinephrine. Do not use Epinephrine, Dopamine or other sympathomimetic agents with beta-agonist activity, as beta stimulation will aggravate hypotension in the event of alpha receptor blockade due to Olanzapine.

Olafast may cause some of the following common side effects:
Weight gain, increased cholesterol and blood triglycerides, increased blood glucose and urine glucose; Increased appetite; Drowsiness, dizziness, restlessness, Parkinson's or dyskinesia; Orthostatic hypotension; Hyperprolactinemia; Increased eosinophil count, pancytopenia or neutropenia; Constipation and dry mouth; Asymptomatic elevation of ALT and AST liver enzymes; Rash; Athritis; Erectile dysfunction in men, decreased sex drive in men and women; Weakness, fatigue; Edema; Fever. Some rare side effects of Olafast:
Hypersensitivity reactions to Olanzapine; Aggravating or exacerbating diabetes, sometimes causing ketoacidosis or coma; Seizures, dystonia, tardive dyskinesia or dysarthria; bradycardia, prolongation of the QT interval; Thrombosis, including pulmonary embolism and deep vein thrombosis; Nosebleed; Distention; Skin increased sensitivity to light; Hair loss; Urinary incontinence or urinary retention; Amenorrhea, enlarged breasts, increased lactation or gynecomastia in men; Decreased platelet count; Neuroleptic malignant syndrome or withdrawal syndrome upon discontinuation of the drug; ventricular tachycardia, ventricular fibrillation, sudden death; Pancreatitis, hepatitis or rhabdomyolysis.

Drug interactions of Olafast that may occur during use are as follows:
Olafast drug used concurrently with Diazepam increases the risk of orthostatic hypotension; Activated charcoal (1g dose) reduces about 60% of Olafast Cmax and AUC, so the use of activated charcoal can be an effective measure to manage Olafast overdose; CYP1A2 inducers may decrease the metabolism of Olafast; Ethanol does not affect the pharmacokinetics of Olanzapine, however the combination of Olafast with alcoholic beverages may increase the risk of orthostatic hypotension; CYP1A2 inhibitors such as Fluvoxamine may decrease the clearance of Olanzapine, so a dose reduction of Olafast should be considered in patients receiving Fluvoxamine; CYP2D6 inhibitors such as fluoxetine cause a slight increase in Cmax and a slight decrease in clearance of olanzapine. However, this change does not affect the effect of Olafast as well as Fluoxetine, so there is no need to adjust the dose; Omeprazole and Rifampin may increase the clearance of Olafast ; Olanzapine acts primarily on the central nervous system, therefore caution should be exercised when Olafast is used in combination with other drugs that also act on the CNS; Olafast may cause hypotension, thereby enhancing the antihypertensive effect of antihypertensive drugs; Olafast is antagonistic to Levodopa and Dopamine agonists; In vitro studies in human liver microsomes have shown that olanzapine is unlikely to inhibit CYP1A2, CYP2C9, CYP2D6 and CYP3A. Therefore, Olafast is unlikely to cause any significant drug interactions related to drug-metabolizing enzymes.

Caution should be exercised when prescribing Olafast to elderly patients with dementia-related mental or behavioral disorders because of possible increased mortality (mainly from cardiovascular causes or bacterial infections). ). Use of Olafast in the treatment of dopamine agonist-associated psychosis in patients with Parkinson's disease is not recommended. In clinical trials, worsening of Parkinson's symptoms and the appearance of hallucinations were reported more frequently when compared with patients receiving placebo and concurrently Olafast was no more effective than placebo in the treatment of these conditions. psychotic symptoms. Neuroleptic Malignant Syndrome (NMS) is a serious side effect of antipsychotic drugs, however reports of NMS associated with Olafast are rare. Clinical manifestations of NMS include high fever, muscle spasticity, altered mental status, and symptoms of autonomic instability (such as irregular pulse or blood pressure, tachycardia, sweating). or arrhythmia) in combination with other manifestations such as increased creatine phosphokinase, myoglobinuria, and acute renal failure. Patients with symptoms of NMS or unexplained high fever should immediately discontinue all antipsychotics, including Olafast. Olafast should be used with caution in diabetic patients, because of the risk of hyperglycemia or the onset of an exacerbation of diabetes, sometimes causing ketoacidosis, coma or even death. Patients should be clinically monitored in combination with blood glucose testing at the following times: before taking Olafast, 12 weeks later and once a year. Patients with diabetes or at risk of diabetes should have their blood glucose monitored regularly before taking Olafast, after 4 weeks, 8 weeks, 12 weeks and every 3 months. Dyslipidemia occurred in Olafast-treated patients in placebo-controlled clinical trials. This condition should be managed clinically appropriately, particularly in patients with dyslipidemia or at risk of dyslipidemia. Patients treated with antipsychotics such as Olafast should have their blood lipids checked prior to administration, 12 weeks after initiation of treatment, and every 5 years thereafter. Olafast has anticholinergic activity in vitro, but clinical trials are rare. Due to limited clinical experience, Olafast should be used with caution in patients with prostatic hypertrophy, intestinal obstruction/paralysis or angle-closure glaucoma. Liver enzymes such as ALT (Alanine amino transferase), AST (Aspartate amino transferase) sometimes increase transiently, without symptoms, especially at the beginning of treatment with Olafast. Therefore, patients taking Olafast should be carefully monitored if the test is elevated in ALT or AST, has symptoms of liver failure, a history of liver failure, and is taking hepatotoxic drugs. Once hepatitis is confirmed, treatment with Olafast must be stopped immediately. Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea or vomiting have been reported (rarely) with abrupt discontinuation of Olafast. Clinical trials have observed clinically significant QT prolongation in patients receiving Olafast, however, no significant difference in cardiovascular events was observed when compared with placebo. However, caution should be exercised when Olafast is co-administered with drugs known to prolong the QT interval, especially in patients who are elderly, have congenital long QT syndrome, congestive heart failure, myocardial hypertrophy, hypokalemia or blood magnesium. Caution should be exercised when prescribing Olafast in patients with a history of epilepsy or with factors that lower the seizure threshold. In comparative studies of 1 year or less duration, the incidence of dyskinesia in patients treated with olanzapine was statistically significantly lower. However, the risk of tardive dyskinesia is increased with long-term use of Olafast. Therefore, consideration should be given to dose reduction or discontinuation of Olafast when signs or symptoms of tardive dyskinesia appear. Orthostatic hypotension was rarely observed in the elderly during clinical trials of Olanzapine. Patients should have their blood pressure measured periodically if they are over 65 years old. Olafast can cause drowsiness, so care should be taken when administering the drug to people who drive or operate machinery. There are no adequate and tightly controlled studies with the use of Olafast in pregnant patients. Patients should inform their doctor if they become pregnant or intend to become pregnant during treatment with Olafast. Due to limited experience in this population, Olafast should only be used in pregnant women when the benefits outweigh the risks to the fetus. Neonates exposed to antipsychotic drugs (including Olafast) during the third trimester of pregnancy are at risk for adverse events, including extrapyramidal syndrome and withdrawal symptoms, with duration and severity. different severity after birth. Studies in lactating women have shown that Olanzapine is excreted in human milk at concentrations of only about 1.8% of the dose. However, Olafast is not recommended for women who are breastfeeding. Olafast is an antipsychotic product with the active ingredient Olanzapine. Olafast is indicated for the treatment of certain neurological conditions. To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.